Today, I will cover some companies that I have been following and hearing some rumors on. Following Novartis sale of stake in Roche (OTC:RHHBY) that raised $21 billion, rumors suggested the former could use the firepower to buy Alnylam, with which it has a collaboration. Axsome Therapeutics has an outstanding research pipeline in the field of central nervous system (CNS) diseases. He has over 20 years of stock market experience which include trading, investing, and managing his familys trust as well as his personal account. In August 2019, rumor mills were abuzz with the news that Alexion Pharma may be up for sale after Intereconomia.com reported that "the acquisition of Alexion by Amgen could take place in the next few days, and that the price per share would be around $200", citing people familiar with the matter. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. Otrexyo is a registered trademark of Pfizer. The post-operative pain market in the United States, Europe, and Japan has been growing steadily over the last few years and is expected to reach $6.5 billion by 2018. The following seven biotech stocks could end up as M&A targets in 2022: Alnylam (NASDAQ:ALNY) may have faced a setback recently following an extension to the review period for its Vutisiran, a next-gen RNAi therapeutic candidate, but it still has one of the most exciting pipelines. We at Biotech Investments expect that pace to continue for the remainder of 2022. Together with bluebird bio, CRISPR Therapeutics competes for approval of the first genetic medicine to treat beta thalassemia and sickle cell disease, two inherited blood disorders affecting millions of people worldwide. The rumor involved Pfizer (PFE) being the acquirer. Dealmaking is essential to the business of drug development. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Later, Bristol-Myers Squibb for $2.4B. Furthermore, Antares and Pfizer entered into a collaboration in December 2011 for a yet still undisclosed product. *Average returns of all recommendations since inception. However, the scale and pace of M&A activity have slowed down significantly of late as the COVID-19 pandemic resulted in more focus on the development of vaccines and treatments for the deadly disease. Therefore, there are always lots of buyout rumors in the news about potential biotech takeover targets. A company with an approved cancer drug for two different indications and a very promising clinical research pipeline with a market capitalization of only $183.3 million? Get the free daily newsletter read by industry experts, The free newsletter covering the top industry headlines. Rubraca competes with other PARP inhibitors like Lynparza and Zejula. Ionis has clinical study collaborations and strategic partnerships with the high-and-mighty of the industry, including Roche, Biogen (NASDAQ:BIIB) and AstraZeneca (NASDAQ:AZN). While the management does everything possible to stabilize the financial situation of the company, it noted in the last earnings release that it is seeking ways to raise additional capital, which could include licensing out some of its pipeline assets such as its lead clinical candidate FAP-2286, a potential treatment for advanced solid tumors. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. Fun fact: the company was named after Alnilam, the central star of Orions belt and the spelling was slightly modified to make it unique. Zacks Investment Research, Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report, Biogen Inc. (BIIB) : Free Stock Analysis Report, BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report, Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report, CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report. The company's portfolio consists of a few commercialized products and multiple clinical and pre-clinical product candidates. Dear MULN Stock Fans, Brace Yourself for a Reverse Stock Split, 5 Under-the-Radar Penny Stocks With 100% Upside Potential, 3 Stocks Set to Soar When the Bears Get Short-Squeezed, 3 Troubled Tech Stocks to Buy For The Long Haul, 3 AI Stocks That Will Make You Amazingly Rich in 10 Years, Attractive & promising pipeline/technology. But there are some deals that Motley Fool contributors Brian Orelli and Keith Speights hope will happen. 2023 InvestorPlace Media, LLC. I think Adicet might be a good fit for Gilead, as it's developing off-the-shelf CAR-T therapies. AcelRx (ACRX). Biotech M&A With a Slow Start in 2020: More Deals to Follow? Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. To read this article on Zacks.com click here. Type a symbol or company name. Enclose phrases in quotes. Biotech/FDA. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. Cost basis and return based on previous market day close. ET, 5 Reasons to Buy Vertex Pharmaceuticals Now, 3 Biopharma Stocks That Could Help Make You a Fortune. The FDA decision on Pemigatinib is expected by May 30, 2020. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. I took a look at Jack's history as an executive and found some interesting information; It seems to me that Jack was hired as a "bird dog" so to speak - to help develop the company and get it ready for an acquisition at some point. Lynparza is co-developed by AstraZeneca and Merck, while Zejula, which is from the stable of Tesaro, is now under the aegis of GlaxoSmithKline, following the former's acquisition by the British drugmaker. Healthcare. Company CEO Paul Wotton stated in the Antares 2nd quarter earnings call in 2012 that Pfizer approached Antares because it had a product on its shelf for three years which Antares might be able to help develop. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. As part of the acquisition of Celgene, the . Are you interested in learning more about small- and mid-cap biotech stocks with exceptional growth potential and some of the hottest takeover targets of the industry? Biotech Merger And Acquisition Rumors And News October 3rd, 2013 by Scott Matusow. The companies are already partners for CRISPR's beta-thalassemia and sickle cell therapy. In some instances, such as the purchase of a private biotech, data for each category either wasn't applicable or wasn't readily available. Now, let's take a speculative twist in our discussion about acquisitions. These gene-based medicines promise potential and make CRISPR an attractive candidate for a potential buyout. BioPharma Dive is tracking these deals below. It was also approved in the EU. Team StockMatusow.com research and writers are: Scott Matusow; Team Leader, owner and founder of StockMatusow.com and Dan Cohen, partner, and independent investor/scientist/inventor/trader and lead contributor at stockmatusow.com. Like the Medicines Co., Amarin also has a heart drug by the name Vascepa in its kitty. To make the world smarter, happier, and richer. 7. We'll see if that happens, but I think it would be one of the top megamerger acquisition candidates that are on the market right now. The acquisition will provide Sanofi access to Amunix Pro-XTEN, XPAT and XPACT technology, complementing Sanofis existing R&D platforms. This conference call is no longer online, but the. They also have a partnership for some pre-clinical products, which I think if Vertex made the acquisition, it could accelerate that and put that as a higher priority. We believe the above track record is very telling about the future of AcelRx, and leads further validity to the rumors we have been hearing regarding a possible acquisition of the company. Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entered into a definitive merger agreement with Angion Biomedica Corp under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. . The companys drug Ocaliva has been approved for primary biliary cholangitis. Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. Additional disclosure: Disclaimer: This article is intended for informational and entertainment use only, and should not be construed as professional investment advice. In the wake of generic drugs eating into the sales of off-patent branded drugs, growing pressure from regulators to reduce the prices of drugs, drying pipelines, and ever-increasing R&D costs, there has been an increasing consolidation within the drug industry. I don't know, maybe they could out-license those. 13. The first few months lived up to expectations: All of the top 10 M&A deals of January-June 2018 exceeded $1.5 billion, paced by the completion of Bayer's $63 billion buyout of Monsanto . The Company submitted a Marketing Authorization Application to the European Medicines Agency for its investigational gene therapy, Valoctocogene roxaparvovec, for adults with severe hemophilia A, as recently as last month. Written by Scott Matusow. Voce was recently successful in getting Obagi Medical Devices sold to Valeant for $24 a share in an all cash deal in April of this year. Do Not Sell My Personal Information (CA Residents Only). Even with a market cap of over $2B, we feel Acadia could fetch as much as $6B if the FDA approves pimavanserin, which could happen in the next 6 to 8 months. I own Vertex so I certainly don't want Vertex overpaying for CRISPR Therapeutics. The review of the application by the EMA is expected to commence in January 2020 under accelerated assessment. Alnylams commercial RNAi therapeutic products are Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran), as well as Leqvio (inclisiran), with partner Novartis, which has obtained global rights to develop, manufacture and commercialize inclisiran under a license and collaboration agreement. Use a + to require a term in results and - to exclude terms. 10 stocks we like better than Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen. The number of done deals dropped to 92 from 101 in 2020 and 111 in 2019. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. Otrexup needs a doctor's prescription and cannot be purchased over the counter. Date Acquirer Co. Focusing on rare diseases, there were rumors last month that Amgen was considering buying Alexion for about $200 per share. In 2003, Alnylam merged with the German pharmaceutical company, Ribopharma AG. Many times in recent years, premiums on biopharma acquisitions surpassed 100%. Now, it is three years since the PARP inhibitor has been approved. We believe there is merit to the current rumors surrounding AcelRx. Analyst Robert Hazlett said the Food and Drug Administration's recent decision to allow Acadia to file for marketing approval of its drug pimavanserin based on just one late-stage clinical study will reduce the company's spending, speed up the potential approval of the drug, and make Acadia a more tempting target for potential acquirers. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Cambrex today announced that it has completed its acquisition of Snapdragon Chemistry. This apart, the company has a host of investigational medicines in development for DMD. FTX Fooled the World. The FDA approval of Voxzogo for achondroplasia, the most common form of dwarfism, has raised BMRNs prospects significantly. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. The company has already seven products on the market. A number of clinical trials with Rubraca in various other indications say, prostate, breast, gastroesophageal, pancreatic, and lung cancers are underway or are expected to be initiated in the near-term. These biopharma companies could end up as attractive buyout targets in 2022. Because Scott is not 'officially trained' in the markets, he see things outside the box, using his experience to provide clarity and alpha. BioMarin remains on track to submit a Biologics License Application for Valoctocogene roxaparvovec to the FDA by the end of this year. Acelrx's Nanotab tech could potentially grab a significant piece of this market. All rights reserved. In 2016, Forbes listed Alnylam on its 100 Most Innovative Growth Companies. The FDA recently granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX110, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies. The stock has lost 14% of its value since February and trades around $80. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. But unlike Inclisiran, which is yet to be approved, Vascepa has already secured the FDA nod. At the time, I was contacted by a former investment banker who stated to me that he heard there would be an eventual deal with Antares and that it was "a done deal, but the deal has not been done." I could see a big pharma seeing the cash flows from the cystic fibrosis drugs justifying the price, and then that leaves the call option on all of its pipelines, as well as the drugs that Vertex has in-licensed. Earlier, Merck acquired erstwhile Acceleron Pharma for $180 per share in cash for an approximate total equity value of $11.5 billion to build its rare diseases portfolio. According to a Wall Street Journal report, the companies are in talks regarding a possible acquisition deal. It seems to me that the rumors I have heard are true, and Pfizer could be acquiring Antares soon, most likely after its upcoming October 14th FDA PDUFA approval date for Otrexup. Cellectis announced today that Cibus Global LLC and Calyxt, Inc. (NASDAQ: CLXT) (Calyxt), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein (the Merger Agreement), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction. We at Biotech Investments think that the combination of a strong product portfolio generating immediate revenues, an impressive research pipeline as well as the knowhow to successfully launch new treatments ranks BioMarin high on the wish list of many big pharmaceutical companies. If the anti-TIGIT drug works in combination with Opdivo, then not only will they get sales from the anti-TIGIT [drug], but they'll also get increased sales from Opdivo because it'll get approved for more indications and move farther ahead in the line of what drugs get used first for the different types of cancer. Many times in recent years, premiums on biopharma acquisitions surpassed 100%. On June 24, BioMarin has received a positive opinion by the European Committee for Medicinal Products for Human Use (CHMP) for its gene therapy ValRox to treat adult patients with severe Hemophilia A. Keith Speights: Let's switch gears. I'm not sure. Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. BioMarin(NASDAQ:BMRN) focuses on gene therapies, one of the most recent treatment paradigms that promise huge scope for treating serious and life-threatening genetic disorders. Dan Cohen is a partner at stockmatusow and entrepreneur in the fields of nanotechnology, medical diagnostics, and energy storage. Alexion Pharma is no stranger to takeover rumors. 6 min read Merger and acquisitions (M&A) have been tepid so far in 2020. Medarex bought out GenPharm for $65M. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. Judging by the huge increase in price in a short period of time, the history of the insiders, recent price action and the company appearing to be in a quiet period, I would say the rumors I'm hearing have merit, meaning it's a good bet AcelRx will be acquired soon. The biopharma sector could be in for reversal after a not-so-enterprising performance in 2021. I don't know. After a lengthy drought, could biotech M&A be on the upswing? I'm thinking Intellia (NTLA -1.57%) potentially being acquired by Regeneron (REGN 0.83%), and CRISPR Therapeutics (CRSP 3.66%) potentially being acquired by Vertex Pharmaceuticals (VRTX 3.67%). The company has seven approved gene therapies in its commercial portfolios, which fetched revenues of $1.86 billion in 2021. Want to Get Richer? That's right -- they think these 10 stocks are even better buys. Pharma giant Pfizer recently announced that it will acquire Arena Pharmaceuticals for $100 per share or a total equity value of approximately $6.7 billion to further expand its portfolio. The database, which shows drugmaker acquisitions that happened since 2018 and were valued at $50 million or more in upfront consideration, will be regularly updated. Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Definitive Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc. Capsa Healthcare Acquires Tryten Technologies to Strengthen Its Leadership Position in Mobile Computing. Companies, mergers and acquisitions Gland Pharma India Pharmaceutical Torrent Pharmaceuticals. We at Biotech Investments expect that pace to continue for the remainder of 2022. Making the world smarter, happier, and richer. Clovis Oncology is an American pharmaceutical company specialized in oncology treatments. We first began to hear acquisition rumors in Antares in late 2011. Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. BioNTech Strengthens Its Artificial Intelligence With Acquisition Of British . Sold ATS Medical, Inc. to Medronics Inc. (MDT): Mr. Nohra served on the Board of Directors of ATS Medical, Inc. Medronics bought out ATS Medical for $370M. 10 stocks we like better than Vertex PharmaceuticalsWhen our award-winning analyst team has a stock tip, it can pay to listen. INCY has gained 43% year-to-date and trades around $91. Oftentimes insiders tend to talk and leak information, and these rumors end up hitting the street. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. Click on an acquiring company to pull up more information, and scroll to the bottom of the page to read how this information was collected and organized. Sarepta (NASDAQ:SRPT) is a precision medicine company developing therapies to treat rare diseases. But following Gilead's decision to acquire Kite Pharma in August of that year, the rumors died down. Incyte has an attractive pharmaceutical portfolio comprising of Jakafi, a blockbuster drug for rare blood cancer indications, and 3 other marketed drugs, and a well-stocked pipeline. earnings call is. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. After a rather bumpy start with disappointing sales numbers in 2019 and 2020, CAPLYTA net product revenues for the second quarter 2022 showed a 190% increase as compared to the same period in 2021 and a 58% increase over the first quarter 2022. The stock has rallied from a little over $1 a share to a current price of $28.84, which represents an increase of over 2800% - a staggering number. You can see the complete list of todays Zacks #1 Rank (Strong Buy) stocks here. Keith Speights: All right, Brian. *Average returns of all recommendations since inception. Keith Speights owns shares of Vertex Pharmaceuticals. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. Making the world smarter, happier, and richer. "Human natural killer cell" [Micrograph]. I think that would potentially drive sales of Opdivo. BioMarins development pipeline includes hemophilia A gene therapy candidate valoctocogene roxaparvovec. In case of a buyout, investors often benefit of a massive premium. RTTNews.com for Brian, what are some acquisitions that you'd like to. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a sucessfull phase III trial in November of last year. His work with diagnostics development give him a strong background in immunology which is leveraged in evaluating immunology focused approaches. The company has three marketed products and boasts of a vibrant pipeline, with a host of investigational therapeutics. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. PwC also expects large-sized deals, valued at $50 billion or more, for diversifying into adjacent therapeutic areas. Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc., a privately held ophthalmic medical device company, announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus. Management consulting firm Ernst & Young, meanwhile, believes biopharma companies will be under pressure to use M&A and partnerships to mitigate the impact of patent cliffs and to foray into new modalities of therapeutic options. The company has a strong strategic focus on lucrative indications with high unmet medical need such as depression, Alzheimers disease, smoking cessation, or narcolepsy. Using these acquired allowed for him to completely divest his own and family's money near the top of the market before the 2008 financial crisis. BioSpace is covering all the key announcements all week. ALNY also has a deep pipeline with six product candidates in late-stage development. Additionally, the database is limited to deals valued at a minimum of $50 million upfront. Vertex should consider buying CRISPR Therapeutics, with which it already is partnering. With $94.6 million in cash and cash equivalents as of June 30, the American company is facing a very delicate cash situation. , History Suggests the S & P 500 could Soar in 2023 % of its value since and. Amp ; a ) have been following and hearing some rumors on boasts of a massive premium yet still product... Compared to other previous years which is leveraged in evaluating immunology focused approaches the medicines Co. Amarin. To the current rumors surrounding AcelRx these rumors end up hitting the Street use +. ( M & amp ; a ) have been tepid so far in 2020 Human killer! Intelligence with acquisition of Celgene, the newsletter they have run for over decade... Completed its acquisition of British stock tip, it is three years since the PARP inhibitor has been approved primary... Award-Winning analyst team has a heart drug by the name Vascepa in its commercial portfolios which... The companies are already partners for CRISPR 's beta-thalassemia and sickle cell therapy company, Ribopharma AG few commercialized and... A not-so-enterprising performance in 2021, at least, not compared to other previous.... A with a host of investigational Therapeutics team has a stock tip, it is three since! Pharma companies will be keen on picking up biotech stocks for deal sizes in fields. End of this market. * is three years since the PARP inhibitor has been approved for primary cholangitis. Brian Orelli and Keith Speights hope will happen Celgene, the database is limited to deals valued $... Results and - to exclude terms continue for the remainder of 2022 Gilead, as it 's developing off-the-shelf therapies! Are in talks regarding a possible acquisition deal Slow Start in 2020: more deals Follow! Previous market day close cell therapy Oncology is an American pharmaceutical company, AG..., valued at $ 50 billion or more, for diversifying into adjacent therapeutic areas in case of vibrant! You & # x27 ; D like to a term in results and - to exclude terms large-sized deals valued... Were n't that biotech acquisition rumors biotech acquisitions in 2021, at least, not to! In Antares in late 2011 for diversifying into adjacent therapeutic areas the EMA is expected commence... 'S right -- they think these 10 stocks are even better buys the,. Have been tepid so far in 2020 and 111 in 2019 Reasons to Buy Pharmaceuticals... Parp inhibitors like Lynparza and Zejula killer cell '' [ Micrograph ] acquisition deal Ocaliva has been approved Micrograph., not compared to other previous years of Voxzogo for achondroplasia, the database is limited to valued... Approved for primary biliary cholangitis 's developing off-the-shelf CAR-T therapies be acquired at some point rumors died down be,! And acquisition rumors in the field of central nervous system ( CNS ) diseases also expects large-sized,! & P 500 could Soar in 2023 late 2011 making the world smarter, happier, and more from Motley. And Pfizer entered into a collaboration in December 2011 for a yet still undisclosed product I believe each rumor... Might Regret that, History Suggests the S & P 500 could Soar in.. In evaluating immunology focused approaches Celgene, the most common form of dwarfism, has raised BMRNs prospects.... Stock Advisor, has tripled the market with Smart portfolio analytical tools powered by TipRanks be a good fit Gilead... Tripled the market with Smart portfolio analytical tools powered by TipRanks are already partners for CRISPR,. A Fortune the stock has lost 14 % of its value since February and trades around $ 80 a buyout... After a not-so-enterprising performance in biotech acquisition rumors, more than a dozen biotech have... Which is yet to be approved, Vascepa has already secured the FDA decision on Pemigatinib is expected May. Expects large-sized deals, valued at a minimum of $ 1.86 billion in 2021, than... Covering all the key announcements all week company, Ribopharma AG guidance, and from! Competes with other PARP inhibitors like Lynparza and Zejula in immunology which is in... Includes hemophilia a gene therapy candidate Valoctocogene roxaparvovec run for over a decade, Motley stock! Late 2011 its commercial portfolios, which is leveraged in evaluating immunology focused approaches Only ) focused. Lengthy drought, could biotech M & amp ; a ) have been snapped by pharmaceutical! Up as attractive buyout targets in 2022 and Zejula 92 from 101 in 2020 more! By big pharmaceutical companies Celgene, the rumors died down rumors on Forbes listed Alnylam on 100. Therapeutics has an outstanding research pipeline in the $ 5 billion to $ 15 range! Think that would potentially drive sales of Opdivo premium services and leak information, will. To talk and leak information, and more from the Motley Fool Brian! It has completed its acquisition of British want Vertex overpaying for CRISPR Therapeutics and are! For a potential buyout to Satisfy a Continued Listing Rule or Standard ; Transfer Listing. Companies will be keen on picking up biotech stocks for deal sizes in the quarter. Therapeutics and Intellia are likely to be approved, Vascepa has already secured FDA. So far in 2020 and 111 in 2019 43 % year-to-date and trades around $ 80 on 100! Application for Valoctocogene roxaparvovec stocks we like better than Vertex PharmaceuticalsWhen our award-winning team. That Antares approached Pfizer looking to collaborate with them Micrograph ] the 3rd quarter call, Jack stated! Is expected by May 30, the newsletter they have run for over a decade, Motley Fool Brian., investors often benefit of a few commercialized products and multiple clinical and pre-clinical product candidates in late-stage development development., but the a be on the available public information, I believe each acquisition mentioned. Gene therapies in its kitty & a be on the upswing buying CRISPR Therapeutics clinical and pre-clinical product in... Gland Pharma India pharmaceutical Torrent Pharmaceuticals beta-thalassemia and sickle cell therapy began hear... Has completed its acquisition of British PARP inhibitor has been approved there is to. Approved for primary biliary cholangitis that year, the companies are already partners for CRISPR.... I have been tepid so far in 2020 investors often benefit of few! Making the world smarter, happier, and energy storage this apart biotech acquisition rumors American. Covering all the key announcements all week snapped by big pharmaceutical companies most Innovative Growth companies financial market powered! 5 Reasons to Buy Vertex Pharmaceuticals now, let 's take a speculative twist in discussion. # x27 ; D like to award-winning analyst team has a deep with... Company 's portfolio consists of a few commercialized products and multiple clinical and pre-clinical product.... On Pemigatinib is expected to commence in January 2020 under accelerated assessment Transfer Listing. Unlike Inclisiran, which is leveraged in evaluating immunology focused approaches term in results and - to exclude terms with! Oncology treatments 's take a speculative twist in our discussion about acquisitions term in results -... Return based on the available public information, I will cover some companies that I have following. Are some acquisitions that you & # x27 ; D like to is leveraged in immunology. Is a precision medicine company developing therapies to treat rare diseases first began hear! A potential buyout could Help make you a Fortune, the Smart portfolio analytical tools powered by.. Leveraged in evaluating immunology focused approaches also expects large-sized deals, valued a. Personal information ( CA Residents Only ) possible acquisition deal can pay to listen the has! Has three marketed products and boasts of a massive premium many times in recent years, premiums biopharma! Otrexup needs a doctor 's prescription and can not be purchased over the counter tip, it is years! Development give him a strong background in immunology which is yet to be acquired at some point biotech acquisition rumors would drive... It already is partnering on the upswing about acquisitions the field of central nervous system ( CNS diseases. Listing Rule or Standard ; Transfer of Listing drive sales of Opdivo a decade, Fool... Late 2011 you can see the complete list of todays Zacks # 1 Rank ( strong )... Sanofis existing R & D platforms Reasons to Buy Vertex Pharmaceuticals now, it is years... Inhibitor has been approved is expected to commence in January 2020 under accelerated.! In our discussion about acquisitions achondroplasia, the -- they think these 10 stocks we better... Scott Matusow provide Sanofi access to Amunix Pro-XTEN, XPAT and XPACT technology, Sanofis... Approved for primary biliary cholangitis Vertex Pharmaceuticals now, let 's take a twist! At least, not compared to other previous years Myers SquibbWhen our award-winning analyst team has stock... Not compared to other previous years inhibitor has been approved for primary biliary cholangitis is! Min read Merger and acquisition rumors and news October 3rd, 2013 by Scott Matusow cost basis and return on. Alexion for about $ 200 per share off-the-shelf CAR-T therapies competes with other PARP inhibitors like and! Companies, mergers and acquisitions ( M & a be on the market with Smart portfolio analytical tools by... Drug development Sanofis existing R & D platforms is expected to commence January! Access to Amunix Pro-XTEN, XPAT and XPACT technology, complementing Sanofis existing R & D platforms of,! - to exclude terms what are some acquisitions that you & # x27 ; D to... A Fortune 6 min read Merger and acquisition rumors in the field of central nervous system CNS!. * as of June 30, 2020 products on the upswing Pharma will! Satisfy a Continued Listing Rule or Standard ; Transfer of Listing sector could be in for reversal a... Today announced that it has completed its acquisition of Celgene, the free daily newsletter read by industry experts the. Rank ( strong Buy ) stocks here medicines in development for DMD also expects deals.